+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration



Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration



Nephron 40(3): 286-291



Patients with chronic renal failure showed the existence of phosphate retention, secondary hyperparathyroidism, and reduced production of 1,25-(OH)2D. In order to determine the effect of correction of hyperphosphatemia on secondary hyperparathyroidism and vitamin D metabolism in those patients, 7 nondialyzed patients with chronic renal failure were treated with large doses of A1(OH)3 (15-18 g/day) to correct their high levels of serum phosphate. After treatment with A1(OH)3, serum phosphate fell significantly (p less than 0.005) from 6.3 +/- 1.3 (mean +/- SD) to 3.7 +/- 0.5 mg/dl. Serum parathyroid hormone decreased significantly (p less than 0.02) from 2.87 +/- 1.64 to 1.85 +/- 1.26 ngEq/ml. Serum 1,25-(OH)2D was low compared to the normal mean level before A1(OH)3 administration and decreased significantly (p greater than 0.02) from 19.4 +/- 6.1 to 11.4 +/- 4.3 pg/ml after the treatment. Aluminum levels increased significantly (p greater than 0.02) from 1.7 +/- 1.0 to 3.6 +/- 1.5 micrograms/dl. Serum calcium, calcitonin, and 25-(OH)D showed no significant change. Our data suggested that the suppression of secondary hyperparathyroidism by A1(OH)3 treatment results in a decrease of the 1,25-(OH)2D level in patients with chronic renal failure, even though their hyperphosphatemia has been corrected. We speculate that aluminum loading might play a role in diminishing the secretion of parathyroid hormone and the production of 1,25-(OH)2D in humans.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 006403047

Download citation: RISBibTeXText

PMID: 3839293

DOI: 10.1159/000183480


Related references

The effect of aluminum hydroxide on the calcium phosphorus and aluminum balances the serum parathyroid hormone and the aluminum content of bone in patients with chronic renal failure. Clinical Research 19(4): 806, 1971

The effect of aluminum hydroxide on calcium phosphorus and aluminum balances the serum parathyroid hormone concentration and the aluminum content of bone in patients with chronic renal failure. Clinical Science 43(4): 519-531, 1972

Effect of aluminum hydroxide on calcium phosphorus and concentration and the aluminum content of bone in patients aluminum balances the serum parathyroid hormone with chronic renal failure. Australian & New Zealand Journal of Medicine 3(4): 423, 1973

Relationship of serum aluminum to serum creatinine and parathyroid hormone in chronic renal failure and transplant patients. Proceedings of the Clinical Dialysis and Transplant Forum 7: 86-90, 1977

Parathyroid hormone and dihydroxy vitamin d 3 responses to reduction of serum phosphate in advanced chronic renal failure. Clinical Science 67(SUPPL 9): 65P-66P, 1984

Effect of vitamin d metabolites on parathyroid hormone pth synthesis in chronic renal failure in rats. Kidney International 37(1): 467, 1990

The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure. Clinical Science 43(4): 519-531, 1972

Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure. British Medical Journal 284(6318): 776-778, 1982

Deficiency in parathyroid hormone enhances brain aluminum and 1 25 dihydroxyvitamin d administration mitigates bone aluminum uptake in dogs with renal failure and long term aluminum administration. Clinical Research 35(3): 510A, 1987

Deficiency in parathyroid hormone pth enhances brain aluminum and 1 25 dihydroxyvitamin d administration mitigates bone aluminum uptake in dogs with renal failure and long term aluminum administration. Kidney International 31(1): 354, 1987

Influence of vitamin d treatment on serum levels of parathyroid hormone fragments in patients with chronic renal failure. Norman, A Al (ed.). Vitamin D And Problems Related To Uremic Bone Disease. Proceedings Of The Second Workshop. Wiesbaden, West Germany, Oct. 27-30, . Xxiv 779p. Illus. Walter De Gruyter: Berlin, West Germany; New York, N.y., U.s.a. ISBN 3-11-005775-1: 629-633, 1975

Intestinal calcium absorption, serum phosphate, and parathyroid hormone in patients with chronic renal failure and osteodystrophy before and during hemodialysis. Calcified Tissue Research 26(2): 119-126, 1978

Association between vitamin D receptor FokI. Polymorphism and serum parathyroid hormone level in patients with chronic renal failure. Journal of Endocrinological Investigation 28(2): 117-121, 2005

The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances and the plasma parathyroid hormone in patients with chronic renal failure. Clinical Science 41(2): 5p-6p, 1971

Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Calcified Tissue International 36(2): 133-138, 1984